Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series

Bibliography

• Saphris® (asenapine) sublingual tablets. Product information (PI). N.V. Organon, a subsidiary of Merck & Co. Inc, Roseland, USA; 2009
   Google Scholar
• Sycrest® (Asenapine). Summary of Product Characteristics. 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/001177/WC500096895.pdf
   Google Scholar
• Cortese L, Bressan RA, Castle DJ, Mosolov SN. Management of schizophrenia: clinical experience with asenapine. J Psychopharmacol 2013;27(4 Suppl):14-22
   PubMedGoogle Scholar
• Samalin L, Charpeaud T, Llorca PM. Asenapine in bipolar I disorder: evidence and place in patient management. Ther Adv Chronic Dis 2013;4(1):5-14
   PubMedGoogle Scholar
• Szegedi A, Zhao J, van Willigenburg A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011;11:101
   PubMed Web of Science ®Google Scholar
• Stoner SC, Pace HA. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther 2012;34(5):1023-40
   PubMed Web of Science ®Google Scholar
• Pompili M, Venturini P, Innamorati M, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat 2011;7:259-65
   PubMed Web of Science ®Google Scholar
• Reynolds GP. Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on Asenapine. Ther Adv Psychopharmacol 2011;1(6):197-204
   PubMedGoogle Scholar
• Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23(1):65-73
   PubMed Web of Science ®Google Scholar
• Frånberg O, Marcus MM, Ivanov V, et al. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009;204(2):251-64
   PubMed Web of Science ®Google Scholar
• Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68(16):2269-92
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Thompson PM, Moore TA. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 2011;5:333-41
   PubMed Web of Science ®Google Scholar
• Warren CG, Dubovsky SL. New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania. Neuropsychiatr Dis Treat 2013;9:753-8
   PubMed Web of Science ®Google Scholar
• Young AH, Altamura AC, Gonzalez-Pinto AM, et al. Use of asenapine in clinical practice for the management of bipolar mania. J Psychopharmacol 2013;27(4 Suppl):3-13
   PubMed Web of Science ®Google Scholar
• Gerrits MG, de Greef R, Dogterom P, Peeters PA. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. J Clin Pharmacol 2012;52(5):757-65
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008;172:177-97
   PubMed Web of Science ®Google Scholar
• EMEA. Assessment Report Sycrest. 2010. Available from: http://www.ema.europa.eu/docs/enGB/document_library/EPAPublic_assessment_report/human/001177/WC500096898.pdf
   Google Scholar
• Gao K, Mackle M, Cazorla P, et al. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat 2013;9:1145-57
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005;27(5):289-304
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010;126(3):358-65
   PubMed Web of Science ®Google Scholar
• Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry 2013;75(3):238-45
   Web of Science ®Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68(10):1492-500
   PubMed Web of Science ®Google Scholar
• Choi YK, Wong EH, Henry B, et al. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13(3):405-10
   PubMed Web of Science ®Google Scholar
• Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009;49(11):1297-308
   PubMed Web of Science ®Google Scholar
• Schoemaker J, Stet L, Vrijland P, et al. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry 2012;45(5):196-203
   PubMed Web of Science ®Google Scholar
• Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011;72(3):349-55
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
   PubMed Web of Science ®Google Scholar
• Szegedi A, Calabrese J, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder. Results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Kohli S, Singh V. Use of asenapine in a case of treatment-resistant bipolar disorder. Prog Neurol Psychiatry 2013;17(6):7-8
   Google Scholar
• Buoli M, Dobrea C, Caldiroli A, et al. Augmentative asenapine in a recurrent manic catatonic patient with partial response to clozapine. Case Rep Psychiatry 2013;2013:503601
   PubMedGoogle Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166(9):980-91
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov
   Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Pyschiatry 2009;10(2):85-116
   PubMed Web of Science ®Google Scholar
• Yatham L, Kennedy S, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1-44
   PubMed Web of Science ®Google Scholar
• Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-15
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58(1):85-91
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and metaanalysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115:12-20
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007;64:442-55
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14(3):154-219
   PubMed Web of Science ®Google Scholar
• Yildiz A, Vieta E, Leucht S, Baldessarini R. Efficacy of antimanic treatments: metaanalysis of randomized, controlled trials. Neuropsychopharmacology 2011;36(2):375-89
   PubMed Web of Science ®Google Scholar
• Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004;174(1):17-24
   PubMed Web of Science ®Google Scholar
• Minassian A, Young JW. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother 2010;11(12):2107-15
   PubMed Web of Science ®Google Scholar
• Siegel SJ, Irani F, Brensinger CM, et al. Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 2006;163(3):433-41
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010;18(3):143-57
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental health disorders. 5th edition. Washington, DC, American Psychiatric Association; 2013
   Google Scholar
• Kusumakar V, Yatham LN, Haslam DR. Treatment of mania, mixed state, and rapyd cycling. Can J Psychiatry 1997;42(Suppl 2):79S-86S
   PubMedGoogle Scholar
• McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11(7):673-86
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122(1-2):27-38
   PubMed Web of Science ®Google Scholar
• Michalak EE, Guiraud-Diawara A, Sapin C. Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials. Curr Med Res Opin 2014;30(4):711-71
   PubMed Web of Science ®Google Scholar